ArticleGut and liver2016
Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.
Article in Gut and liver, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Preventable Cancers Caused by Infection in Korea From 2015 to 2030.Journal of Korean medical science · 2025Pooled it
- Proportion and Characteristics of Helicobacter Pylori -Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Systematic Review and Meta-Analysis.Clinical and translational gastroenterology · 2025Pooled it
- Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial.The Lancet. Haematology · 2024Trial
- Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma: a retrospective study in regions with a high prevalence of Helicobacter pylori infection.BMC gastroenterology · 2026Article
- Clinical management of gastric mucosa-associated lymphoid tissue lymphoma.The Korean journal of internal medicine · 2026Review
- Best Treatment Options for Severe Helicobacter pylori Infections.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Long-term Clinical Efficacy of Radiotherapy for Patients with Stage I-II Gastric Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A Retrospective Multi-institutional Study.Cancer research and treatment · 2025Article
- Mucosal healing of ileum-mucosa-associated lymphoid tissue lymphoma afterFrontiers in oncology · 2025Article
- [Characteristics of Gastric Mucosa-associated Lymphoid Tissue Lymphoma in Korea].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Review
- Long-term Outcomes and Prognostic Factors of Gastric MALT Lymphoma.Journal of gastric cancer · 2024Article
- Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy forJCO oncology practice · 2024Article
- How aging influences the gut-bone marrow axis and alters hematopoietic stem cell regulation.Heliyon · 2024Review
- Review
- Targeted delivery of a short antimicrobial peptide (CM11) against Helicobacter pylori gastric infection using concanavalin A-coated chitosan nanoparticles.Journal of materials science. Materials in medicine · 2023Article
- Endoscopic and Histopathological Characteristics of Gastrointestinal Lymphoma: A Multicentric Study.Diagnostics (Basel, Switzerland) · 2023Article
- An Overview of Selected Bacterial Infections in Cancer, Their Virulence Factors, and Some Aspects of Infection Management.Biology · 2023Review
- Signaling pathways of oxidative stress response: the potential therapeutic targets in gastric cancer.Frontiers in immunology · 2023Review
- Synchronous early gastric and intestinal mucosa-associated lymphoid tissue lymphoma in aWorld journal of clinical cases · 2022Article
- Current Status of the Spectrum and Therapeutics ofCancers · 2022Review
- Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma in the Gastrointestinal Tract in the Modern Era.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsWe investigated the effectiveness of Helicobacter pylori eradication therapy for gastric mucosaassociated lymphoid tissue (MALT) lymphoma regardless of the H. pylori infection status or disease stage.
methodsFrom November 1995 to September 2014, 345 subjects who were diagnosed with gastric MALT lymphoma and had received eradication therapy as their first-line treatment were eligible for inclusion in this study. A retrospective review was performed using the medical records.
resultsOf the 345 patients, H. pylori infection was detected in 317 patients (91.9%). The complete remission (CR) rate after eradication therapy was 82.3%, which was higher in H. pylori -positive patients than in H. pylori-negative patients (84.5% vs 57.1%, p=0.001). CR rates after eradication did not present significant differences between stages, and the CR rate was 83.3% for stage IE1 and 74.4% for stage IE2 or above (p=0.167). The overall CR rate was 87.2% after additional treatment, and neither H. pylori infection status nor stage showed differences according to the treatment response.
conclusionsEradication therapy led to CR in 57.1% of H. pylori-negative patients and in 74.4% of patients with stage IE2 or above. Eradication therapy is worthwhile as an initial treatment for gastric MALT lymphoma regardless of the H. pylori infection status and stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.